Q1 2024 Lab Market Overview

Sale activity continues to be at a standstill. Landlords remain hopeful that the market will bounce back and provide sufficient returns on their investments.

Leasing activity compared to recent years still remains down comparatively. A lack of funding in the life science sector continues to be a driving factor.

An influx of $2.6B in secondary offerings for public life science companies in Q1 2024 indicates the stress for mature companies to hit to profitability. For perspective, only one publicly traded Bay Area HQd company that received secondary offering funds in Q1 is listed as generating revenue.